MedTrace Logo

Ruxolitinib for Chuvash Polycythemia

NCT01730755 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2018-05-14

No results posted yet for this study

Summary

Chuvash polycythemia (CP) is a rare form of congenital polycythemia caused by mutations in the VHL gene. Currently, there are no therapies that have proven effective for CP. Recent studies have demonstrated that VHL (von Hippel-Lindau tumor suppressor) regulates the activity of JAK2 (Janus kinase 2). In mouse models, inhibition of JAK2 reverses the CP phenotype. Therefore, the investigators hypothesize that JAK2 inhibition may have significant clinical benefits for CP patients.

Conditions

  • Erythrocytosis, Familial, 2

Interventions

DRUG

Ruxolitinib

Ruxolitinib 10 mg tablets twice daily

Sponsors & Collaborators

  • Incyte Corporation

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01730755 on ClinicalTrials.gov